Overall market sentiment has been neutral on Corvus Pharmaceuticals Inc (CRVS) stock lately. CRVS receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With CRVS Stock Today?
Corvus Pharmaceuticals Inc (CRVS) stock is trading at $3.51 as of 10:42 AM on Friday, Feb 26, a loss of -$0.07, or -1.96% from the previous closing price of $3.58. The stock has traded between $3.31 and $3.69 so far today. Volume today is light. So far 822,555 shares have traded compared to average volume of 1,316,975 shares.
More About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small-molecule and antibody agents that target the immune system to treat patients with cancer. The firm's pipeline includes CPI-006, CPI-818, CPI-935, and others.